Optogenetic gene therapy partly restores vision in clinical trial

The short version

• Researchers reported that an optogenetic gene therapy paired with specialized goggles safely restored partial sight in six of ten trial participants.[The Guardian]
• The therapy was tested on people with advanced retinitis pigmentosa, a genetic condition that damages the retina's primary light-sensing cells.[The Guardian]
• Patients improved at basic tasks like locating doorways, but current methods cannot restore high-resolution vision or facial recognition.[The Guardian]

Key facts

• The clinical trial evaluated ten patients with advanced retinitis pigmentosa, monitoring their outcomes for up to five years.[The Guardian]
• The procedure delivers genetic code for a light-sensitive protein into retinal ganglion cells via a single viral injection, accompanied by light-pulsing goggles.[The Guardian]
• Six of the ten participants attained clinically meaningful gains in light sensitivity and improved on navigation tasks such as locating doors.[The Guardian]
• No systemic adverse effects were detected across five years, and the only severe ocular side effect ended within minutes.[The Guardian]

Sources

Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.

• Gene therapy can partly restore sight in blind people, researchers revealThe Guardian - Science